Clinical Profile and Outcome of Children With

0 downloads 0 Views 94KB Size Report
Paraneoplastic opsoclonus had a poor outcome in our experience. Keywords opsoclonus-myoclonus syndrome, neuroblastoma, paraneoplastic syndrome.
Original Article

Clinical Profile and Outcome of Children With Opsoclonus-Myoclonus Syndrome

Journal of Child Neurology 2014, Vol 29(1) 58-61 ª The Author(s) 2013 Reprints and permission: sagepub.com/journalsPermissions.nav DOI: 10.1177/0883073812471433 jcn.sagepub.com

Pratibha Singhi, MD1, Jitendra Kumar Sahu, DM1, Jhuma Sarkar, MD1, and Deepak Bansal, MD2

Abstract The opsoclonus-myoclonus syndrome is a distinct disorder characterized by opsoclonus, myoclonus, and ataxia, along with marked irritability and behavioral changes. Worldwide, data on its epidemiology, clinical features, and outcome are scarce. The aim of the study was to determine the clinical profile and outcome of children with this disorder. A retrospective study of all children admitted with a diagnosis of opsoclonus-myoclonus from 2000 to 2012 was done. Outcome was assessed on followup by direct assessment and by telephonic interview. Eleven patients with a diagnosis of opsoclonus-myoclonus were admitted over a 12-year period. Of the 11, 4 had paraneoplastic etiology. Children with paraneoplastic opsoclonus had more relapses and a poor outcome as compared to an idiopathic group. Paraneoplastic opsoclonus had a poor outcome in our experience. Keywords opsoclonus-myoclonus syndrome, neuroblastoma, paraneoplastic syndrome Received September 11, 2012. Received revised October 16, 2012. Accepted for publication November 23, 2012.

The opsoclonus-myoclonus syndrome is a distinct disorder of acute/subacute onset characterized by opsoclonus, myoclonus, ataxia, marked irritability, and/or sleep disturbance in children.1 The first detailed description of this entity was provided by Marcel Kinsbourne in 1962 and the disorder was termed Kinsbourne encephalitis.2 Since then, various case reports and case series have been published. It is important to recognize and diagnose this disorder as it is a prototype of pediatric paraneoplastic syndrome and has a striking association with neuroblastoma.3 Also, it is among one of few immunomodulator-re sponsive, pediatric neurologic disorders. Therefore, the diagnosis has therapeutic and prognostic implications. Although both cell-mediated and humoral immune mechanisms are implicated, the pathogenesis remains elusive.4 Recently, role of genetics has also been postulated in its pathogenesis.5 Worldwide, because of rarity of the disease, data on its epidemiology, clinical features, and outcome are scarce. We present a retrospective study on children admitted to the pediatric neurology unit of the Advanced Pediatrics Center, Post-Graduate Institute of Medical Education and Research, from 2000 to 2012 with a diagnosis of opsoclonus-myoclonus. The objective of this study was to describe the clinical profile and outcome of this disorder.

Methods The medical records of all children admitted in the pediatric neurology unit of the department of pediatrics, Post-Graduate Institute of Medical

Education and Research with a diagnosis of opsoclonus-myoclonus from 2000 to 2012, were retrieved and reviewed. Details of clinical symptoms, severity, investigations, and treatment were recorded on a prestructured proforma. The diagnosis of opsoclonus-myoclonus was based on a constellation of any 3 of the 4 clinical features: opsoclonus, myoclonus, ataxia, and irritability/behavioral change.3 Idiopathic opsoclonusmyoclonus was defined as a disorder with no obvious etiology despite detailed workup. Outcome was assessed on follow-up by direct assessment and by telephonic interview. Data were analyzed using the SPSS version 18.0 software (SPSS, Chicago, Illinois). Frequencies and means were calculated by descriptive analysis.

Results A total of 11 patients with a diagnosis of opsoclonusmyoclonus were admitted over the 12-year period (Table 1). The median age at clinical presentation was 1.5 years (range 1-13 years). The male-female ratio was 5:6. 1

Pediatric Neurology Division, Department of Pediatrics, Post-Graduate Institute of Medical Education & Research, Chandigarh, India 2 Pediatric Hematology-Oncology Division, Department of Pediatrics, PostGraduate Institute of Medical Education & Research, Chandigarh, India Corresponding Author: Pratibha Singhi, MD, Pediatric Neurology Division, Department of Pediatrics, Post-Graduate Institute of Medical Education & Research, Chandigarh, India 160012. Email: [email protected]

Downloaded from jcn.sagepub.com by guest on December 27, 2015

59

Downloaded from jcn.sagepub.com by guest on December 27, 2015

13

18

12

24

18

14

15

156

18

12

18

1/F

2/F

3/M

4/F

5/M

6/F

7/F

8/M

9/F

10/M

11/M

No

Antecedent 2 d fever

No

Antecedent fever of 2 d

No

Prodromal fever

Diarrhea 7 d ago

Two d after varicella vaccine

Diarrhea 10 d ago

No

Fever for 1 d

Antecedent history

Irritability

Irritability

Irritability

Anger behavior

Irritability

Irritability, aggression Irritability

Lethargy

Irritability, aggression

Irritability

Irritability

Behavioral symptoms

IVIG

ACTH failed, response with IVIG

Intravenous methylprednisolone pulses followed by oral corticosteroids IVIG, surgery cyclophosphamide,

ACTH, surgery, cyclophosphamide

Treatment

Idiopathic

Idiopathic

Idiopathic

Idiopathic

Spontaneous recovery

ACTH

Oral corticosteroids

Oral corticosteroids

Ganglioneuroblastoma IVIG, surgery cyclophosphamide, (suprarenal) Idiopathic Oral corticosteroids

Idiopathic

Neuroblastoma (retroperitoneum)

Neuroblastoma (paraaortic)

Idiopathic

Neuroblastoma left suprarenal

Etiology

Abbreviations: ACTH, adrenocorticotrophic hormone; IVIG, intravenous immunoglobulin; M, male; F, female.

Age at onset (in mo)

Serial no./ sex

Table 1. Clinical Profile at Presentation and Outcome in 11 Children With Opsoclonus-Myoclonus Syndrome.

0

0

0

0

0

1

0

1

4

1

19

6

1

24

12

24

12

10

1

0

9

0

At 18 mo follow-up, delayed motor milestones, aggression, frequent awakening during sleep, age- appropriate language, and cognitive skills At 18 mo follow-up, significant motor and cognitive impairment, delayed language, no ocular abnormality At 3.5 y follow-up, complete motor and ocular recovery, learning difficulty At 5.5 y follow-up, speech stuttering, learning difficulty At 21 mo follow-up, normal development At 2 y follow-up, mild slurring of speech and gait deficits At 2 y follow-up, mild motor impairment and gaze abnormalities At 3 y follow-up, asymptomatic, normal development At 3.5 y follow-up, asymptomatic, normal development

At 9 mo follow-up, mild motor and ocular abnormalities, sleep difficulty, frequent awakening during sleep At 16 mo follow-up, complete recovery, normal development

Duration of Relapses symptoms (mo) Outcome

60

Journal of Child Neurology 29(1)

All children had normal development before the onset of symptoms. Opsoclonus, myoclonus, ataxia, and encephalopathy were present in all during the clinical course. Irritability, ataxia, and motor regression were the earliest features. Symptoms were moderate to severe in all. Sleep disturbance was present in all. The median duration of symptoms at the time of presentation was 2 months (range 2 days to 12 months). The reasons for the delay in diagnosis included delayed referral, and misdiagnoses by referring pediatricians (such as viral encephalitis, acute cerebellar ataxia, and Guillain-Barre´ syndrome). Of the 11, 4 children had paraneoplastic opsoclonus (2 with retroperitoneal neuroblastoma, 1 with suprarenal ganglioneuroblastoma, and 1 with suprarenal neuroblastoma). Onset of neurologic symptoms preceded the diagnosis of tumor in all the 4 cases. The tumor was detected on contrast-enhanced computed tomogram (CT) of the abdomen in all the 4 cases. It was missed on ultrasound abdomen in 3 cases. Iodine-123 metaiodobenzylguanidine scintigraphy scan was performed in 3 cases and it detected tumor in 1 case. Tests for urinary excretion of homovanillic acid and vanillylmandelic acid were negative in all cases. Three children had atypical presentations. One child (case 2) presented with acute onset ataxia and irritability but without opsoclonus. An initial diagnosis of acute cerebellar ataxia was made and she was treated with intravenous methylprednisolone pulses followed by oral corticosteroids. She had a good response and recovered completely by 4 weeks. However, soon after stopping of corticosteroids at 12 weeks, she had recurrence of symptoms this time with opsoclonus. A diagnosis of opsoclonus-myoclonus syndrome was made and she was treated again with methylprednisolone pulses followed by oral corticosteroids with which she recovered completely. A detailed evaluation for neuroblastoma was negative. One child (case 4) had onset of symptoms 2 days after varicella vaccine. She was later diagnosed with neuroblastoma. One child (case 8) had late symptom onset at 13 years, and recovered with oral steroids. Of the 7 cases with idiopathic opsoclonus-myoclonus patients, 3 were treated with oral corticosteroids, 1 with adrenocorticotrophic hormone, 1 with intravenous immunoglobulin, and 1 with methylprednisolone pulses followed by oral corticosteroids. One child had spontaneous improvement and complete recovery without specific immunomodulator therapy. Of the 4 cases with paraneoplastic opsoclonus-myoclonus syndrome; 3 were treated with tumor resection, chemotherapy, and intravenous immunoglobulin. In 1 child, adrenocorticotrophic hormone followed by intravenous immunoglobulin were given, but tumor resection and chemotherapy were deferred as parents were not willing for surgery. Relapse of opsoclonus-myoclonus symptoms occurred in 3 cases. Two of them had paraneoplastic opsoclonus-myoclonus, and 1 had idiopathic. Five cases had complete recovery. All of them were idiopathic. All 4 cases with paraneoplastic etiology had mild to moderate sequelae. Of the 4 cases, 2 had sleep difficulty in form of frequent sleep disruptions; 1 had persistent aggressive behavior, 1 had significant cognitive and motor impairment, and 1 had learning difficulty.

Discussion Our study represents the largest case series from India and has important observations. It illustrates the rarity of the syndrome in our population, similar to other studies. According to data from the United Kingdom, the estimated incidence of this syndrome was 0.18 new cases per million total populations per year.1 The prolonged duration of symptoms prior to referral and initial misdiagnoses highlights the fact that most pediatricians in our country are not aware of the syndrome. Pediatricians making the diagnosis of acute cerebellar ataxia in a toddler should be aware of possibility of opsoclonusmyoclonus syndrome. The existence of opsoclonus excludes the diagnosis of acute cerebellar ataxia. The presence of excessive irritability or sleep disturbances in coexistence of acute-onset ataxia, even in the absence of opsoclonus, should raise the suspicion of opsoclonus-myoclonus syndrome. Akin to previously published studies, we observed a similar median age at clinical presentation, no gender bias, common antecedent illness, acute/subacute onset of presentation, association of neuroblastoma, and response to immunomodulator therapy.1,6 However, in contrast with the reported high sensitivity (up to 95%) of metaiodobenzylguanidine scintigraphy scan for detection of neuroblastoma, we found that its sensitivity for tumor detection was low as compared to an abdominal CT scan. We also observed poor sensitivity of urine catecholamines in our cases. Similarly, Brunklaus and colleagues7 have reported poorer sensitivities for metaiodobenzylguanidine scintigraphy scan and urine catecholamines, reflecting the stage of maturation and predominant neurotransmitters of the cells comprising these tumors.8 In our series, only 4 of 11 cases had paraneoplastic opsoclonus-myoclonus syndrome. Previously published studies have reported a paraneoplastic etiology in about 50% of children.6 However, none of the investigative modalities has a 100% sensitivity to detect neuroblastoma; also, this tumor is known to have spontaneous regression. Therefore, a possibility of a very small tumor that escaped detection even after investigations and regressed spontaneously cannot be excluded.9 We observed a good therapeutic response with immunomodulators, including adrenocorticotrophic hormone, intravenous immunoglobulin, and parenteral and oral corticosteroids. It is difficult to compare these therapies because of the small number of patients. One child with paraneoplastic opsoclonusmyoclonus failed to respond with adrenocorticotrophic hormone but had a significant response with intravenous immunoglobulin. In recent studies, rituximab, an anti-CD 20 monoclonal antibody, has been shown to be effective and safe for treatment of pediatric opsoclonus-myoclonus syndrome.10,11 We were not able to use rituximab in our patients because of cost constraints. Recently, Tate and colleagues12 conducted the largest study on comparison of adrenocorticotrophic hormone-based immunotherapies for pediatric opsoclonus-myoclonus syndrome. They reported greater efficacy of adrenocorticotrophic hormone–based multimodal therapy compared with adrenocorticotrophic hormone alone and greater response to adrenocorticotrophic hormone than

Downloaded from jcn.sagepub.com by guest on December 27, 2015

Singhi et al

61

corticosteroid-based therapy.12 There are also anecdotal reports of benefit with topiramate, clonazepam, and oral high-dose dexamethasone pulses.13–15 Neurologic relapses in our series were less than those reported by Tate and colleagues (up to 52 %).6 This could perhaps be due to the small number of patients in our study. Also, in our series, the outcome was better in those with idiopathic opsoclonus-myoclonus syndrome whereas in the study by Tate and colleagues, the outcome was independent of etiology. Interestingly, Bataller and colleagues16 have also observed better outcome of idiopathic opsoclonus-myoclonus syndrome in adult patients. Mitchell and colleagues17 described development and neurologic sequelae in 17 children with opsoclonusataxia caused by neuroblastoma. They observed substantial developmental sequelae and increased deficits in older children. They postulated that this represents a progressive encephalopathy rather than a time-limited single insult.17 We did not observe progressive developmental and behavioral syndrome in our patients, which could be due to small number of patients of paraneoplastic etiology, short-follow-up, and lack of objective psychometric testing. Brunklaus and colleagues18 studied clinical predictors of long-term outcome and demonstrated that severe initial symptoms and very young age at disease onset are important risk factors of developing long-term sequelae. To conclude, opsoclonus-myoclonus syndrome is a rare but one of the few immunomodulator-responsive pediatric neurologic disorders. Screening for an occult neuroblastoma is necessary in children with the syndrome. Paraneoplastic opsoclonus had a poor outcome in our experience. Author Contributions PS and JKS conceptualized the study design. PS, JKS, JS, and DB were involved in data collection and draft of manuscript. All coauthors contributed in critical review of manuscript.

Declaration of Conflicting Interests The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding The authors received no financial support for the research, authorship, and/or publication of this article.

Ethical Approval The study design was approved by the institute ethics committee.

References 1. Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/ opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol. 2010;14:156-161. 2. Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatr. 1962;25:271-276.

3. Sahu JK, Prasad K. The opsoclonus-myoclonus syndrome. Pract Neurol. 2011;11:160-166. 4. Pranzatelli MR. The neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol. 1992;15:186-228. 5. Blumkin L, Kivity S, Lev D, et al. A compound heterozygous missense mutation and a large deletion in the KCTD7 gene presenting as an opsoclonus-myoclonus ataxia-like syndrome. J Neurol. 2012;259:2590-2598. 6. Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonusmyoclonus syndrome. J Pediatr Oncol Nurs. 2005;22:8-19. 7. Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child. 2012;97:461-463. 8. Aydin GB, Kutluk MT, Yalcin B, et al. The prognostic significance of vanillylmandelic acid in neuroblastoma. Pediatr Hematol Oncol. 2010;27:435-448. 9. Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 2005;228:275-282. 10. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J. Pediatr Hematol Oncol. 2006;28:585-593. 11. Battaglia T, De Grandis E, Mirabelli-Badenier M, et al. Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments. Eur J Paediatr Neurol. 2012; 16:192-195. 12. Tate ED, Pranzatelli MR, Verhulst SJ, et al. Active comparatorcontrolled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome. J Child Neurol. 2012;27:875-884. 13. Fernandes TD, Bazan R, Betting LE, da Rocha FCG. Topiramate effect in opsoclonus-myoclonus-ataxia syndrome. Arch Neurol. 2012;69:133. 14. Paliwal VK, Chandra S, Verma R, Kalita J, Misra UK. Clonazepam responsive opsoclonus myoclonus syndrome: additional evidence in favour of fastigial nucleus disinhibition hypothesis? J Neural Transm. 2010;117:613-615. 15. Oguma M, Morimoto A, Takada A, et al. Another promising treatment option for neuroblastoma-associated opsoclonusmyoclonus syndrome by oral high-dose dexamethasone pulse: lymphocyte markers as disease activity. Brain Dev. 2012;34: 251-254. 16. Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124(Pt 2):437-443. 17. Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonusataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics. 2002;109:86-98. 18. Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics. 2011;128:e388-e394.

Downloaded from jcn.sagepub.com by guest on December 27, 2015